Table 2.
Analyses of the association between baseline clinical features and biomarkers with change of MoCA scores over 2 years and with MoCA score at 2 years in patients with newly diagnosed Parkinson’s disease
| Change in MoCA score
|
MoCA follow-up score at 2 year follow-up
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis
|
Multivariate analysis
|
Univariate analysis
|
Multivariate analysis
|
|||||
| Coefficient | p value | Coefficient | p value | Coefficient | p value | Coefficient | p value | |
| Demographic and clinical characteristics | ||||||||
|
| ||||||||
| Age | 0·061 | 0·0001* | 0·045 | 0·01 | −0·106 | <0·0001* | −0·049 | 0·003* |
| Sex | ||||||||
| Women | Ref | Ref | ||||||
| Men | 0·167 | 0·61 | .. | .. | −0·764 | 0·03* | .. | .. |
| Education | −0·059 | 0·28 | .. | .. | 0·064 | 0·30 | .. | .. |
| Disease duration | −0·034 | 0·13 | .. | .. | −0·001 | 0·96 | .. | .. |
| Motor subtype | ||||||||
| Tremor-dominant | Ref | Ref | Ref | Ref | ||||
| Postural instability and gait difficulty | 0·268 | 0·57 | .. | .. | −0·047 | 0·96 | .. | .. |
| Indeterminate | 0·585 | .. | 0·172 | .. | ||||
| MoCA baseline score | 0·667 | <0·0001* | 0·572 | <0·0001* | ||||
| GDS score | 0·070 | 0·25 | .. | .. | −0·063 | 0·35 | .. | .. |
| MDS-UPDRS motor score | 0·038 | 0·03* | .. | .. | −0·068 | 0·0004* | .. | .. |
| UPSIT score | −0·064 | 0·001* | −0·035 | 0·08 | 0·089 | <0·0001* | 0·045 | 0·01 |
| RBDSQ score | 0·075 | 0·15* | .. | .. | −0·078 | 0·18* | .. | .. |
|
| ||||||||
| APOE, CSF, and DAT imaging markers | ||||||||
|
| ||||||||
| APOE ε4 status | ||||||||
| No APOE ε4 allele | Ref | Ref | Ref | |||||
| Heterozygous | 0·740 | 0·03* | 0·658 | 0·01 | −0·532 | 0·33 | .. | .. |
| Homozygous | 2·240 | 3·701 | −1·047 | .. | .. | |||
| DAT imaging (striatal binding ratio) | ||||||||
| Mean putaminal uptake | −0·798 | 0·14* | .. | .. | 1·122 | 0·06* | .. | .. |
| Mean caudate uptake | −0·641 | 0·02* | .. | .. | 0·574 | 0·06* | .. | .. |
| Putaminal asymmetry | −0·470 | 0·21 | .. | .. | 0·900 | 0·03* | .. | .. |
| Caudate asymmetry | 0·804 | 0·39 | .. | .. | 0·414 | 0·69 | .. | .. |
| CSF markers, pg/mL | ||||||||
| Aβ42 | −0·006 | 0·0002* | .. | .. | 0·004 | 0·02* | .. | .. |
| α-synuclein | −0·0003 | 0·21 | .. | .. | 0·0001 | 0·57 | .. | .. |
| α-synuclein (participants with haemoglobin <200 ng/mL)† | −0·0003 | 0·23 | .. | .. | 0·0001 | 0·68 | .. | .. |
| Total tau | 0·019 | 0·03* | .. | .. | −0·035 | 0·0004* | .. | .. |
| Phosphorylated tau | −0·003 | 0·83 | .. | .. | −0·010 | 0·56 | .. | .. |
| Aβ:tau ratio | −0·197 | 0·0002* | −0·125 | 0·03 | 0·271 | <0·0001* | 0·162 | 0·002 |
| Total protein | 0·015 | 0·07* | .. | .. | −0·018 | 0·05* | .. | .. |
Ref=reference. MoCA=Montreal Cognitive Assessment. GDS=Geriatric Depression Scale. MDS-UPDRS=Movement Disorder Society Unified Parkinson’s Disease Rating Scale. UPSIT=University of Pennsylvania Smell Inventory Test. RBDSQ=Rapid eye movement sleep behaviour disorder Screening Questionnaire. DAT=dopamine transporter.
Included in multivariate linear regression analysis (p<0·2).
n=302.